Juno Therapeutics Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Juno Therapeutics (JUNO) Misses Q2 EPS by 23c
August 4, 2016 4:45 PM EDTJuno Therapeutics (NASDAQ: JUNO) reported Q2 EPS of ($0.64), $0.23 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $14.26 million.
For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.
... More


